PREVENT: Q-Griffithsin Enema for HIV Prevention

Phase 1, randomised, double-blind trial of q-griffithsin in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoints: Number and frequency of adverse events Grade 2 or higher and genitourinary adverse events Grade 1 or higher at 8 weeks, Proportion of participants who report product characteristics to be considered a barrier in study product use and 5 more. Started Jul 2019; status: terminated.